AL
ESPR icon

Airain Ltd’s Esperion Therapeutics ESPR Stock Holding History

Airain Ltd’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-15,774
Closed -$351K – 862
2015
Q4 		$351K Buy
15,774
+6,398
+68% +$161K 0.02% 554
2015
Q3 		$221K Buy
+9,376
New +$588K 0.01% 685

Other funds holding ESPR

AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
Pentwater Capital Management
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CCI
Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return
BB Biotech
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Discovery Capital Management
Discovery Capital Management South Norwalk, Connecticut $2.41B AUM 286.33% 1-Year Est. Return
Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return

Airain Ltd's ESPR Position: Q1 2016 in Review

Airain Ltd sold out of Esperion Therapeutics (ESPR) in Q1 2016, closing a stake of 15,774 shares — an estimated $351K sold.

Airain Ltd first reported a position in ESPR in Q3 2015 and held it in 2 quarters. The position peaked at $351K in Q4 2015. 109 funds tracked by Wall St. Rank hold ESPR as of Q1 2016.

  • Airain Ltd reported no remaining Esperion Therapeutics position as of Q1 2016 after selling out during the quarter.
  • Airain Ltd sold 15,774 Esperion Therapeutics shares in Q1 2016, an estimated $351K.
  • Airain Ltd first reported a position in Esperion Therapeutics in Q3 2015 and held it in 2 quarters.
  • Airain Ltd's Esperion Therapeutics position peaked at $351K in Q4 2015.
  • 109 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2016.

Based on Airain Ltd's 13F filing for Q1 2016, filed 9 May 2016.